CRI Technology Impact Award
CRI Technology Impact Award supports technology developers and clinical cancer immunologists in creating unbuilt, untested technologies to overcome barriers and enable more effective cancer immunotherapies.
Browse similar grants
Funder: Cancer Research Institute
Due Dates: November 15, 2026 (Letter of Intent) | March 1, 2027 (Invited Full Proposal)
Funding Amounts: Up to $600,000 over 2–4 years, plus indirect costs up to 10% of the award total
Summary: Supports unbuilt, untested technologies with transformative potential to overcome barriers in cancer immunotherapy.
Key Information: Applicants must hold a tenure-track position, or an institutionally recognized equivalent, at a nonprofit research institution.
Description
The Cancer Research Institute (CRI) Technology Impact Award provides seed funding for early-stage, pre-development concepts that have not yet been built or tested. It supports visionary, high-risk/high-reward ideas rather than continuation or refinement of existing technologies. By encouraging collaboration between technology developers and clinical cancer immunologists, the program aims to bridge conceptual innovation and clinical application, generate proof-of-principle data, and unlock new biological insights.
Areas of interest include computational systems biology to predict treatment response or resistance, advanced cancer profiling, real-time visualization of immune responses, complex multicellular culture systems modeling tumor–immune interactions, and novel therapeutic technologies that promote tumor immunity. The goal is to create tools, platforms, and systems that enable effective, personalized, and durable cancer immunotherapies.
